Latest News

  • New data analysis on Blue Light Cystoscopy efficiency presented at the virtual BLADDR 2020 congress

    PRESS RELEASE – Oslo, Norway, 16 October, 2020: Photocure ASA (OSE:PHO) today announces a highlight from the BLADDR 2020 congress, a poster presentation on new findings from the Nordic Flexible BLC registry, an ongoing prospective multicenter study. It demonstrates that flexible Blue Light Cystoscopy helped resolve a substantial amount of cases by complete removal on-site or direct referral to intravesical treatment, providing increased efficacy to manage non-muscle-invasive bladder cancer (NMIBC) in the office setting.

    16 Oct 2020
  • Photocure announces new Cevira patent in Europe

    Oslo, Norway, 5 October 2020: Photocure ASA (OSE:PHO) today announces that the European Patent Office (EPO) has granted patent EP 2983780 covering the commercial Cevira® device in Europe until 2034.

    05 Oct 2020
  • Photocure launches European Hexvix operations

    Oslo, Norway, 1 October 2020: Photocure ASA (OSE:PHO) today announces the commencement of the sales, marketing and distribution of Hexvix® in the European markets formerly operated by Ipsen Pharma SAS (Ipsen). The successful transition and launch of European Hexvix operations creates a robust platform for accelerated growth and expansion for Photocure.

    01 Oct 2020
  • Photocure ASA – Share option grant and sale of shares

    Oslo, Norway, 15 September 2020 - The board of directors in Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.

    15 Sep 2020
  • Photocure ASA – share capital increase registered

    Oslo, Norway, 3 September 2020: Reference is made to the stock exchange announcement by Photocure ASA ("Photocure") published 31 August 2020 regarding a share capital increase following the exercise of employee share options.

    03 Sep 2020
  • Exercise of employee share options in Photocure ASA

    Oslo, Norway, 31 August 2020.

    Participants in Photocure ASA's ("Photocure") share option program have on 31 August 2020 exercised a total of 17,366 options, distributed as follows:

    31 Aug 2020
  • Q&A live session with Photocure leadership

    Photocure's CEO Dan Schneider and CFO Erik Dahl will continue their dialogue with stakeholders at a live Q&A session on Wednesday, August 26, 2020, organized by Xtrainvestor on their facebook channel.

    21 Aug 2020
  • Photocure ASA: Results for the second quarter and first half of 2020

    Oslo, Norway, 18 August 2020: Photocure ASA (OSE:PHO) reported Hexvix®/Cysview® revenues of 53.5 million in the second quarter of 2020 (Q2 2019: NOK 52.1), corresponding to growth of three per cent, despite a significant Covid-19 impact in the beginning of the quarter in the U.S. market before a strong recovery towards the end of the period. The company has entered into an agreement with Ipsen Pharma SAS (Ipsen) for the return of Hexvix sales, marketing and distribution rights from the fourth quarter of 2020 and sees significant growth opportunities in Europe. The agreement is expected to be EBITDA accretive from full-year 2021 and beyond.

    18 Aug 2020
  • Photocure ASA: Invitation to presentation of second quarter and first half year 2020 financial results

    Oslo, Norway, 13 August 2020: Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2020 financial results on Tuesday 18 August 2020 at 07:00 CET and invites investors, analysts and the media to a presentation at 14:00 CET the same day.

    13 Aug 2020
  • Photocure appoints Genotests as exclusive partner for Hexvix in Chile

    Oslo, Norway, 13 August 2020: Photocure ASA (OSE: PHO), today announced the appointment of Genotests SpA as the exclusive distributor for the commercialization of Hexvix® in Chile.

    13 Aug 2020
  • Photocure’s partner Asieris Received China NMPA’s Approval to Start a Global Phase III Clinical Trial for APL-1702 (Cevira)

    Shanghai China, July 8, 2020 – Asieris Pharmaceuticals (Asieris), a China-based biotech company with global aspirations to discover, develop and commercialize innovative drugs for the treatment of genitourinary tumors and related diseases, announced today it has received Clinical Trial Approval (CTA) from China’s National Medical Products Administration (NMPA) for the global, multi-centered Phase III clinical trial of its photodynamic drug-device combination product, APL-1702 (Cevira®), which is being developed for the non-surgical treatment of high-grade cervical dysplasia (HSIL).

    08 Jul 2020
  • Photocure appoints Susanne Strauss as Vice President and General Manager of Europe

    Oslo, Norway, 1 July 2020: Photocure ASA (OSE:PHO), today announced the appointment of Susanne Strauss as Vice President and General Manager of Europe, effective 1 July 2020.

    01 Jul 2020
  • Financial calendar for Photocure ASA

    FINANCIAL YEAR 2020

    18.08.2020 - Half-yearly Report

    12.11.2020 - Quarterly Report - Q3

    29 Jun 2020
  • Photocure ASA – New share capital registered

    Oslo, Norway, 26 June 2020: Reference is made to the previous stock exchange notices where Photocure ASA ("Photocure" or the "Company") announced the allocation of 2,500,000 shares at a subscription price of NOK 76 per share, raising gross proceeds of approx. NOK 190,000,000 in a private placement (the "Private Placement"). The shares will be listed on the Oslo Stock Exchange and are tradeable from today, 26 June 2020.

    26 Jun 2020
  • Photocure ASA – Private placement successfully placed

    NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

    24 Jun 2020
  • Photocure ASA - Contemplated Private Placement

    NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

    24 Jun 2020
  • Photocure Enters into Final Agreement to Regain Worldwide Rights of Hexvix

    Oslo, Norway, 11 June 2020: Reference is made to the OSE notification 27 April 2020 from Photocure ASA (Photocure, PHO: OSE) regarding the return of Hexvix® sales, marketing and distribution rights in Europe and other markets currently controlled by Ipsen Pharma SAS (Ipsen). Photocure and Ipsen have today entered into a final agreement.

    11 Jun 2020
  • Photocure ASA – Annual general meeting held

    Oslo, Norway, 10 June 2020: Photocure ASA (OSE: PHO), held its annual general meeting on 10 June 2020 at 17:00 hours (CET).

    10 Jun 2020
  • Photocure ASA: Streaming details for AGM and announcement of sustainability report

    Oslo, Norway, 10 June 2020: Photocure ASA (OSE:PHO) today announces the company’s first sustainability report, which will be presented at the Annual General Meeting (AGM) at 17:00 CET. The AGM will be live streamed and Dan Schneider, President & Chief Executive Officer, will provide a general company update.

    10 Jun 2020